Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “Phenprocoumon”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 217 records · Page 12Linked to original sources

[Case report. Phenprocoumon (Marcumar, Falithrom) as an unusual reason for coumarin poisoning in a dog].

Coumarin poisoning in dogs is not unusual and is in most cases caused by warfarin, a coumarin derivative which is used as a rodenticide. Competitive inhibition of vitamin K with an incomplete synthesis of the coagulation factors II, VII, IX and X can lead to a significant bleeding tendency. We observed a 3-year old male West Highland White Terrier with a reduced general condition and dyspnoea together with a massive haemothorax. Administration of vitamin K1 (3 mg/kg) led to a rapid improvement of the condition. Coagulation analysis revealed a prolonged activated recalcification time (ARCT), prothrombin time (PT) and aPTT with uncharacteristic thrombin time (TT); factor II, VII and X activities were reduced while factor V activity was normal, all of which are characteristic for coumarin poisoning. HPLC did not reveal the presence of warfarin but of phenoprocoumon, a drug used for thromboembolic prophylaxis in humans. This observation has not been described for dogs to date.

Animals↗

[Analysis of phenprocoumon dose regulation based on measurement of coagulation factors II, VII and X].

One hundred anticoagulation treatment records were reviewed retrospectively using stepwise regression analysis to determine the influence of phenprocoumaron on the levels of coagulation factors 2, 7 and 10 (KF) measured relative to normal. The phenprocoumaron dose was expressed relative to the correct maintenance dose determined from the entire record ("overdose", OD measured in mg). Phenprocoumaron treatment influenced the KF over two days, approximately 50% on each day, the total change being -0.03 x OD. Continuous incorrect dosage resulted in KF change, equilibrating at a new level after about four weeks at -0.47 x OD. Similarly, continuous correct dosage in patients with a non-therapeutic FK resulted in equilibration within the therapeutic range after four weeks. For long-term treatment, the dosage was likely to be inaccurate under the following circumstances: 1) if the KF was outside the therapeutic range and moving away from it; 2) if the KF was inside the therapeutic range and the change was greater than 0.05. Algorithms for calculation of phenprocoumaron therapy are presented.

Adolescent↗

On the interaction between the anti-inflammatory substance proquazone (RU 43-715) and phenprocoumone.

In a double blind study on 20 anticoagulated patients, the influence of the anti-inflammatory drug 1-isopropyl-4-phenyl-7-methyl-2 (1H) quinazolone on the degree of hypocoagulability was examined. In comparison to a placebo group, there was no statistical difference in the Quick precentage, in coagulation factors II, VII, and X, and in platelet aggregation induced by collagen and by epinephrine respectively. In addition, no increased bleeding tendency could be observed during the study.

4-Hydroxycoumarins↗